MorphoSys launches Aryla as growth thriller looms
This article was originally published in Scrip
Executive Summary
MorphoSys has flexed its growth muscles by expanding the indications of its lead product and introducing its new technology, Aryla, which it claims will reduce optimisation times by 30% and increase the proportion of programmes reaching clinical development by up to 50%.